KEROBIN LAPAWON: Open Payments
NPI 1255067369 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,741 in 144 payments from 18 companies in 2025. Trend: 2023 $820 · 2024 $1,900 · 2025 $2,741
Food & beverage: $2,630Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $417 |
| ABBVIE INC. | 23 | $405 |
| Teva Pharmaceuticals USA, Inc. | 13 | $304 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $289 |
| Alkermes, Inc. | 10 | $216 |
| Axsome Therapeutics, Inc. | 11 | $185 |
| Neurocrine BioSciences, Inc. | 15 | $175 |
| Lundbeck LLC | 10 | $167 |
| Vanda Pharmaceuticals Inc. | 9 | $158 |
| Janssen Pharmaceuticals, Inc | 4 | $92 |
Products named: REXULTI, VRAYLAR, CAPLYTA, ARISTADA, Auvelity, INGREZZA, FANAPT, UZEDY.
Industry payments across FL — which companies pay providers there.
